Combining antiplatelet and antithrombotic therapy (triple therapy): What are the risks and benefits?

Luis Alejandro Asencio, Jennifer J. Huang, Joseph S. Alpert

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

Most patients with mechanical heart valves and many patients with atrial fibrillation will require long-term anticoagulation therapy. For patients with mechanical prosthetic valves, only warfarin is indicated. However, for patients with nonvalvular atrial fibrillation who are at increased risk for embolic stroke, one of the newer antithrombotic medications, such as rivaroxaban, dabigatran, and apixaban, also can be used. Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor. The risks and benefits of this approach are still not well defined, and current guidelines have included recommendations based primarily on expert opinion.

Original languageEnglish (US)
Pages (from-to)579-585
Number of pages7
JournalAmerican Journal of Medicine
Volume127
Issue number7
DOIs
StatePublished - Jul 2014

Keywords

  • Acute coronary syndrome
  • Anticoagulation
  • Antithrombotic therapy
  • Aspirin
  • Atrial fibrillation
  • Clopidogrel
  • Coronary intervention
  • Coronary stent
  • Drug-eluting stent
  • Platelet inhibitor
  • Stent
  • Triple therapy
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Combining antiplatelet and antithrombotic therapy (triple therapy): What are the risks and benefits?'. Together they form a unique fingerprint.

  • Cite this